Truist Financial’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-29,859
| Closed | -$389K | – | 2608 |
|
|
2020
Q3 | $389K | Sell |
29,859
-2,274
| -7% | -$28.8K | ﹤0.01% | 1856 |
|
|
2020
Q2 | $365K | Sell |
32,133
-2,429
| -7% | -$34.5K | ﹤0.01% | 1809 |
|
|
2020
Q1 | $494K | Sell |
34,562
-2,580
| -7% | -$54.5K | ﹤0.01% | 1565 |
|
|
2019
Q4 | $1.01M | Buy |
37,142
+2,559
| +7% | +$70.4K | ﹤0.01% | 1427 |
|
|
2019
Q3 | $990K | Sell |
34,583
-3,174
| -8% | -$92.5K | 0.02% | 451 |
|
|
2019
Q2 | $1.05M | Sell |
37,757
-8,748
| -19% | -$247K | 0.02% | 446 |
|
|
2019
Q1 | $1.54M | Sell |
46,505
-3,729
| -7% | -$114K | 0.03% | 396 |
|
|
2018
Q4 | $1.46M | Sell |
50,234
-7,438
| -13% | -$268K | 0.03% | 391 |
|
|
2018
Q3 | $2.65M | Sell |
57,672
-12,955
| -18% | -$576K | 0.05% | 322 |
|
|
2018
Q2 | $2.64M | Sell |
70,627
-20,769
| -23% | -$701K | 0.05% | 323 |
|
|
2018
Q1 | $2.7M | Sell |
91,396
-26,941
| -23% | -$912K | 0.05% | 318 |
|
|
2017
Q4 | $4.06M | Sell |
118,337
-31,808
| -21% | -$1.07M | 0.08% | 270 |
|
|
2017
Q3 | $5.43M | Sell |
150,145
-61,260
| -29% | -$1.75M | 0.11% | 234 |
|
|
2017
Q2 | $5.46M | Buy |
211,405
+9,174
| +5% | +$195K | 0.11% | 227 |
|
|
2017
Q1 | $3.88M | Buy |
202,231
+21,058
| +12% | +$373K | 0.08% | 277 |
|
|
2016
Q4 | $3.02M | Buy |
181,173
+26,737
| +17% | +$484K | 0.06% | 306 |
|
|
2016
Q3 | $3.18M | Buy |
154,436
+23,139
| +18% | +$587K | 0.07% | 308 |
|
|
2016
Q2 | $4.02M | Buy |
131,297
+4,853
| +4% | +$169K | 0.08% | 265 |
|
|
2016
Q1 | $4.73M | Sell |
126,444
-3,288
| -3% | -$124K | 0.12% | 197 |
|
|
2015
Q4 | $5.6M | Sell |
129,732
-446
| -0.3% | -$18.8K | 0.15% | 171 |
|
|
2015
Q3 | $4.88M | Sell |
130,178
-7,011
| -5% | -$249K | 0.13% | 194 |
|
|
2015
Q2 | $4.66M | Buy |
137,189
+4,997
| +4% | +$170K | 0.13% | 195 |
|
|
2015
Q1 | $4.68M | Buy |
132,192
+1,959
| +2% | +$70.1K | 0.13% | 184 |
|
|
2014
Q4 | $4.44M | Sell |
130,233
-4,087
| -3% | -$145K | 0.13% | 185 |
|
|
2014
Q3 | $5.18M | Sell |
134,320
-8,748
| -6% | -$326K | 0.16% | 160 |
|
|
2014
Q2 | $5.57M | Sell |
143,068
-3,629
| -2% | -$135K | 0.17% | 148 |
|
|
2014
Q1 | $5.01M | Sell |
146,697
-972
| -0.7% | -$30.1K | 0.16% | 161 |
|
|
2013
Q4 | $3.1M | Buy |
147,669
+6,950
| +5% | +$176K | 0.1% | 220 |
|
|
2013
Q3 | $3.31M | Buy |
140,719
+23,942
| +21% | +$680K | 0.12% | 203 |
|
|
2013
Q2 | $3.14M | Buy |
+116,777
| New | +$3.38M | 0.12% | 209 |
|
Other funds holding MYGN
CCM
GCM
Truist Financial's MYGN Position: Q4 2020 in Review
Truist Financial sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 29,859 shares — an estimated $389K sold.
Truist Financial first reported a position in MYGN in Q2 2013 and held it in 30 quarters. The position peaked at $5.6M in Q4 2015. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.
- Truist Financial reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
- Truist Financial sold 29,859 Myriad Genetics shares in Q4 2020, an estimated $389K.
- Truist Financial first reported a position in Myriad Genetics in Q2 2013 and held it in 30 quarters.
- Truist Financial's Myriad Genetics position peaked at $5.6M in Q4 2015.
- 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.
Based on Truist Financial's 13F filing for Q4 2020, filed 18 Feb 2021.